AU2022303330A1 - Therapeutic nucleic acids and methods of use thereof - Google Patents
Therapeutic nucleic acids and methods of use thereof Download PDFInfo
- Publication number
- AU2022303330A1 AU2022303330A1 AU2022303330A AU2022303330A AU2022303330A1 AU 2022303330 A1 AU2022303330 A1 AU 2022303330A1 AU 2022303330 A AU2022303330 A AU 2022303330A AU 2022303330 A AU2022303330 A AU 2022303330A AU 2022303330 A1 AU2022303330 A1 AU 2022303330A1
- Authority
- AU
- Australia
- Prior art keywords
- nucleic acid
- composition
- subject
- condition
- casein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/056—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163202970P | 2021-07-01 | 2021-07-01 | |
| US63/202,970 | 2021-07-01 | ||
| PCT/US2022/035866 WO2023278799A1 (en) | 2021-07-01 | 2022-06-30 | Therapeutic nucleic acids and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022303330A1 true AU2022303330A1 (en) | 2024-01-18 |
Family
ID=84690648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022303330A Pending AU2022303330A1 (en) | 2021-07-01 | 2022-06-30 | Therapeutic nucleic acids and methods of use thereof |
| AU2022303384A Pending AU2022303384A1 (en) | 2021-07-01 | 2022-06-30 | Formulations for oral delivery of nucleic acids |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022303384A Pending AU2022303384A1 (en) | 2021-07-01 | 2022-06-30 | Formulations for oral delivery of nucleic acids |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240285668A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4363434A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024525512A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240028486A (cg-RX-API-DMAC7.html) |
| CN (2) | CN117897162A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022303330A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3223495A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023278802A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3563859B1 (en) | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
| CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| KR20250078993A (ko) * | 2022-09-30 | 2025-06-04 | 세다르스-신나이 메디칼 센터 | 치료용 핵산 및 그의 사용 방법 |
| KR20260074974A (ko) * | 2023-09-15 | 2026-05-27 | 세다르스-신나이 메디칼 센터 | 유전독성 스트레스를 약화시키고 심장 보호 효과를 발휘하는 trex-1 증강제 |
| WO2026035943A1 (en) | 2024-08-08 | 2026-02-12 | Cedars-Sinai Medical Center | Formulations for oral delivery of nucleic acids |
| WO2026035744A1 (en) | 2024-08-08 | 2026-02-12 | Cedars-Sinai Medical Center | Combination therapies for metabolic disease |
| KR20260065643A (ko) * | 2024-10-31 | 2026-05-11 | 성균관대학교산학협력단 | CU-rich RNA를 포함하는 근위축증 또는 근육 손상의 예방 또는 치료용 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7780873B2 (en) * | 2004-02-23 | 2010-08-24 | Texas A&M University System | Bioactive complexes compositions and methods of use thereof |
| DK2182969T3 (en) * | 2007-07-31 | 2017-02-27 | Univ Texas | Micro-RNA family that modulates fibrosis and its applications |
| CN102639700A (zh) * | 2009-09-30 | 2012-08-15 | 哈佛大学校长及研究员协会 | 通过调节自噬增强基因产物调节自噬的方法 |
| US10258698B2 (en) * | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US20160024575A1 (en) * | 2013-05-02 | 2016-01-28 | The Regents Of The University Of California | Circulating small noncoding rna markers |
| WO2015055857A1 (en) * | 2013-10-18 | 2015-04-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Rny-derived small rnas as biomarkers for atherosclerosis-related disorders |
| CA2962444C (en) * | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| HK1249108A1 (zh) * | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| WO2017136652A1 (en) * | 2016-02-04 | 2017-08-10 | Tarveda Therapeutics, Inc. | Stapled peptide conjugates and particles |
| WO2017193051A1 (en) * | 2016-05-06 | 2017-11-09 | The Trustees Of Princeton University | Methods of monitoring rnase l activity |
| CN111448317B (zh) * | 2017-12-22 | 2025-07-04 | 罗氏创新中心哥本哈根有限公司 | 包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸 |
| EP3749344A4 (en) * | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| US12258594B2 (en) * | 2018-12-05 | 2025-03-25 | The Broad Institute, Inc. | Cas proteins with reduced immunogenicity and methods of screening thereof |
| WO2020131986A1 (en) * | 2018-12-21 | 2020-06-25 | Pioneer Hi-Bred International, Inc. | Multiplex genome targeting |
| WO2026035744A1 (en) * | 2024-08-08 | 2026-02-12 | Cedars-Sinai Medical Center | Combination therapies for metabolic disease |
| WO2026035943A1 (en) * | 2024-08-08 | 2026-02-12 | Cedars-Sinai Medical Center | Formulations for oral delivery of nucleic acids |
-
2022
- 2022-06-30 KR KR1020247003755A patent/KR20240028486A/ko active Pending
- 2022-06-30 JP JP2023581003A patent/JP2024525512A/ja active Pending
- 2022-06-30 AU AU2022303330A patent/AU2022303330A1/en active Pending
- 2022-06-30 KR KR1020247003744A patent/KR20240027814A/ko active Pending
- 2022-06-30 WO PCT/US2022/035870 patent/WO2023278802A1/en not_active Ceased
- 2022-06-30 JP JP2023581043A patent/JP2024527340A/ja active Pending
- 2022-06-30 US US18/572,067 patent/US20240285668A1/en active Pending
- 2022-06-30 AU AU2022303384A patent/AU2022303384A1/en active Pending
- 2022-06-30 CN CN202280059718.0A patent/CN117897162A/zh active Pending
- 2022-06-30 WO PCT/US2022/035866 patent/WO2023278799A1/en not_active Ceased
- 2022-06-30 US US18/571,924 patent/US20250025487A1/en active Pending
- 2022-06-30 CN CN202280059708.7A patent/CN117916249A/zh active Pending
- 2022-06-30 EP EP22834283.8A patent/EP4363434A4/en active Pending
- 2022-06-30 CA CA3223495A patent/CA3223495A1/en active Pending
- 2022-06-30 EP EP22834280.4A patent/EP4362954A4/en active Pending
- 2022-06-30 CA CA3223686A patent/CA3223686A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4362954A1 (en) | 2024-05-08 |
| WO2023278802A1 (en) | 2023-01-05 |
| CA3223686A1 (en) | 2023-01-05 |
| EP4363434A1 (en) | 2024-05-08 |
| JP2024525512A (ja) | 2024-07-12 |
| EP4363434A4 (en) | 2025-06-25 |
| JP2024527340A (ja) | 2024-07-24 |
| CN117897162A (zh) | 2024-04-16 |
| CN117916249A (zh) | 2024-04-19 |
| US20250025487A1 (en) | 2025-01-23 |
| AU2022303384A1 (en) | 2024-01-18 |
| WO2023278799A1 (en) | 2023-01-05 |
| EP4362954A4 (en) | 2026-05-27 |
| CA3223495A1 (en) | 2023-01-05 |
| KR20240027814A (ko) | 2024-03-04 |
| US20240285668A1 (en) | 2024-08-29 |
| KR20240028486A (ko) | 2024-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250025487A1 (en) | Therapeutic nucleic acids and methods of use thereof | |
| US9534219B2 (en) | Methods of treating vascular inflammatory disorders | |
| US20110244059A1 (en) | Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor | |
| US20260053852A1 (en) | Noncoding rna agents (bcyrn1 and derivatives thereof) to treat diseases of immunity | |
| JP6538138B2 (ja) | Herv−wエンベロープタンパク質発現関連疾患において再ミエリン化遮断を治療するための化合物 | |
| WO2010135714A2 (en) | Methods for modulating adipocyte expression using microrna compositions | |
| KR20250078993A (ko) | 치료용 핵산 및 그의 사용 방법 | |
| WO2026035744A1 (en) | Combination therapies for metabolic disease | |
| CN108004310B (zh) | 肾素(原)受体(p)rr基因及其抑制剂的应用 | |
| JP2018519250A (ja) | 治療薬としてのsmad7遺伝子送達 | |
| WO2022026648A1 (en) | Inhibition of incexact1 to treat heart disease | |
| JP7025537B2 (ja) | 抗炎症および抗凝固および器官保護特性を有する核酸分子 | |
| CN112007157B (zh) | Mrg15蛋白或基因作为靶点在代谢疾病治疗和预防中的应用 | |
| JP2013006783A (ja) | 荷重感知遺伝子 | |
| US20220364090A1 (en) | Promotion of Cardiomyocyte Proliferation and Regenerative Treatment of the Heart by Inhibition of microRNA-128 | |
| AU2024340578A1 (en) | Trex-1 augmentation to attenuate genotoxic stress and exert cardioprotection | |
| AU2023385485A1 (en) | Inhibitory nucleic acids and methods of use thereof | |
| TW202526015A (zh) | 靶向LPA基因的RNAi劑及其用途 | |
| WO2024249772A2 (en) | Cpt1 gene therapy and methods for treating or preventing cardiovascular diseases | |
| US20190142968A1 (en) | Compositions and methods for selective inhibition of grainyhead-like protein expression |